2003
DOI: 10.1345/aph.1c523
|View full text |Cite
|
Sign up to set email alerts
|

Reasons for Early Abacavir Discontinuation in HIV-Infected Patients

Abstract: This study shows that abacavir is mainly stopped during the first 6 months of therapy for ADRs. The rate of likely hypersensitivity reaction observed in this study (8.5%) is higher than that observed in clinical trials (5%). After retrospective evaluation, the causality assessment of abacavir is not always certain.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
16
0

Year Published

2004
2004
2013
2013

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 35 publications
(19 citation statements)
references
References 13 publications
3
16
0
Order By: Relevance
“…Through the application of a restrictive definition of definite hypersensitivity, this study is likely to have selected cases with a highly stereotypical immunological response to abacavir exposure, and it must be acknowledged that abacavir also was discontinued in nine individuals (3.6%) with minor symptoms that were not diagnostic of definite abacavir hypersensitivity. These data are consistent with another study involving a fully ascertained cohort of abacavir-exposed individuals in France (n ϭ 331), in which the prevalence of likely hypersensitivity was 8.5%, whereas a further 4.2% ceased abacavir treatment within 6 months because of doubtful hypersensitivity reactions (4).…”
Section: Discussionsupporting
confidence: 91%
See 1 more Smart Citation
“…Through the application of a restrictive definition of definite hypersensitivity, this study is likely to have selected cases with a highly stereotypical immunological response to abacavir exposure, and it must be acknowledged that abacavir also was discontinued in nine individuals (3.6%) with minor symptoms that were not diagnostic of definite abacavir hypersensitivity. These data are consistent with another study involving a fully ascertained cohort of abacavir-exposed individuals in France (n ϭ 331), in which the prevalence of likely hypersensitivity was 8.5%, whereas a further 4.2% ceased abacavir treatment within 6 months because of doubtful hypersensitivity reactions (4).…”
Section: Discussionsupporting
confidence: 91%
“…Approximately 5-9% of patients treated with abacavir develop a hypersensitivity reaction characterized by multisystem involvement that has proved fatal in rare cases (1)(2)(3)(4). Symptoms usually appear within the first 6 weeks of treatment (median time to onset, 11 days) and include fever, rash, gastrointestinal symptoms (nausea, vomiting, diarrhea, or abdominal pain), and lethargy or malaise (3).…”
mentioning
confidence: 99%
“…Abacavir, an HIV nucleoside analogue reverse transcriptase inhibitor causes a potentially lifethreatening hypersensitivity syndrome in approximately 5-8% of recipients within 6 weeks of therapy [207], [208]. The clinical and laboratory features of this syndrome differs from typical cases of DIHS/DRESS in that there is a predilection for the gastrointestinal system with nausea, abdominal pain, diarrhoea, and the respiratory tract with cough, pharyngitis and shortness of Figure 10.…”
Section: Skin Biopsy -Diagnosis and Treatmentmentioning
confidence: 99%
“…Thus, 5-8% of patients that are administered abacavir develop a potentially life-threatening drug hypersensitivity reaction (HSR) characterized by fever, rash and symptoms in the gastrointestinal tract, other organ systems, or both within 6 weeks of initiating therapy [137,138].…”
Section: Abacavirmentioning
confidence: 99%